Advanced serum lipoprotein and glycoprotein profiling for cardiovascular event prediction in type 2 diabetes mellitus: the LIPOCAT study.
Summary
In 933 T2D participants from four Spanish cohorts, advanced 1H-NMR Liposcale/Glycoscale profiling identified higher VLDL-C, remnant IDL-TG, LDL-TG, and glycoproteins A/B in those with CV events. Adding these variables to traditional risk models raised AUROC to 0.756, with similar gains in an external validation cohort.
Key Findings
- Among 933 T2D participants, 104 experienced a CV event during follow-up.
- Elevated VLDL-C, remnant IDL-TG, LDL-TG, and glycoproteins A and B were associated with CV events.
- Adding advanced NMR-derived variables improved AUROC to 0.756, replicated in an external validation cohort.
Clinical Implications
If validated across settings and cost-effective, NMR-based lipoprotein/glycoprotein profiling could refine CV risk assessment in T2D to guide preventive therapies.
Why It Matters
Demonstrates that NMR-derived lipoprotein and glycoprotein metrics add predictive value beyond traditional risk factors for CV events in T2D, supporting precision risk stratification.
Limitations
- Observational design with potential residual confounding and limited generalizability beyond Spanish cohorts.
- Clinical utility and cost-effectiveness of NMR profiling were not evaluated in care pathways.
Future Directions
Prospective implementation studies to test clinical impact and cost-effectiveness, calibration across laboratories, and integration with genomics/omics to build multimodal risk models.
Study Information
- Study Type
- Cohort
- Research Domain
- Diagnosis
- Evidence Level
- II - Prospective cohort analysis with external validation for event prediction.
- Study Design
- OTHER